(INCY) Incyte - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US45337C1027
Stock:
Total Rating 71
Risk 96
Buy Signal 0.62
| Risk 5d forecast | |
|---|---|
| Volatility | 35.3% |
| Relative Tail Risk | -10.7% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.99 |
| Alpha | 26.09 |
| Character TTM | |
|---|---|
| Beta | 0.483 |
| Beta Downside | 0.107 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.01% |
| CAGR/Max DD | 0.28 |
EPS (Earnings per Share)
Revenue
Description: INCY Incyte
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 15.15 > 1.0 |
| NWC/Revenue: 68.25% < 20% (prev 37.66%; Δ 30.59% < -1%) |
| CFO/TA 0.20 > 3% & CFO 1.41b > Net Income 1.29b |
| Net Debt (-3.03b) to EBITDA (1.76b): -1.72 < 3 |
| Current Ratio: 3.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (204.8m) vs 12m ago 3.72% < -2% |
| Gross Margin: 91.80% > 18% (prev 0.91%; Δ 9089 % > 0.5%) |
| Asset Turnover: 82.91% > 50% (prev 77.90%; Δ 5.01% > 0%) |
| Interest Coverage Ratio: 686.5 > 6 (EBITDA TTM 1.76b / Interest Expense TTM 2.43m) |
Altman Z'' 5.35
| A: 0.50 (Total Current Assets 5.02b - Total Current Liabilities 1.52b) / Total Assets 6.96b |
| B: 0.03 (Retained Earnings 213.8m / Total Assets 6.96b) |
| C: 0.27 (EBIT TTM 1.67b / Avg Total Assets 6.20b) |
| D: 0.13 (Book Value of Equity 239.4m / Total Liabilities 1.80b) |
| Altman-Z'' Score: 5.35 = AAA |
Beneish M -3.11
| DSRI: 0.99 (Receivables 1.02b/853.2m, Revenue 5.14b/4.24b) |
| GMI: 0.99 (GM 91.80% / 91.09%) |
| AQI: 0.65 (AQ_t 0.17 / AQ_t-1 0.26) |
| SGI: 1.21 (Revenue 5.14b / 4.24b) |
| TATA: -0.02 (NI 1.29b - CFO 1.41b) / TA 6.96b) |
| Beneish M-Score: -3.11 (Cap -4..+1) = AA |
What is the price of INCY shares?
As of February 28, 2026, the stock is trading at USD 101.27 with a total of 2,027,339 shares traded.
Over the past week, the price has changed by -0.05%, over one month by -2.13%, over three months by -3.05% and over the past year by +38.38%.
Over the past week, the price has changed by -0.05%, over one month by -2.13%, over three months by -3.05% and over the past year by +38.38%.
Is INCY a buy, sell or hold?
Incyte has received a consensus analysts rating of 3.67.
Therefor, it is recommend to hold INCY.
- StrongBuy: 8
- Buy: 3
- Hold: 15
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the INCY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 107.1 | 5.7% |
| Analysts Target Price | 107.1 | 5.7% |
INCY Fundamental Data Overview February 23, 2026
P/E Trailing = 15.8066
P/E Forward = 12.5
P/S = 3.922
P/B = 3.9021
P/EG = 0.1286
Revenue TTM = 5.14b USD
EBIT TTM = 1.67b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 40.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 69.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.03b USD (from netDebt column, last quarter)
Enterprise Value = 16.65b USD (20.16b + Debt 69.4m - CCE 3.58b)
Interest Coverage Ratio = 686.5 (Ebit TTM 1.67b / Interest Expense TTM 2.43m)
EV/FCF = 12.29x (Enterprise Value 16.65b / FCF TTM 1.35b)
FCF Yield = 8.13% (FCF TTM 1.35b / Enterprise Value 16.65b)
FCF Margin = 26.35% (FCF TTM 1.35b / Revenue TTM 5.14b)
Net Margin = 25.03% (Net Income TTM 1.29b / Revenue TTM 5.14b)
Gross Margin = 91.80% ((Revenue TTM 5.14b - Cost of Revenue TTM 421.6m) / Revenue TTM)
Gross Margin QoQ = 90.88% (prev 92.75%)
Tobins Q-Ratio = 2.39 (Enterprise Value 16.65b / Total Assets 6.96b)
Interest Expense / Debt = 0.84% (Interest Expense 582.0k / Debt 69.4m)
Taxrate = 23.25% (90.7m / 389.9m)
NOPAT = 1.28b (EBIT 1.67b * (1 - 23.25%))
Current Ratio = 3.32 (Total Current Assets 5.02b / Total Current Liabilities 1.52b)
Debt / Equity = 0.01 (Debt 69.4m / totalStockholderEquity, last quarter 5.17b)
Debt / EBITDA = -1.72 (Net Debt -3.03b / EBITDA 1.76b)
Debt / FCF = -2.24 (Net Debt -3.03b / FCF TTM 1.35b)
Total Stockholder Equity = 4.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.75% (Net Income 1.29b / Total Assets 6.96b)
RoE = 29.15% (Net Income TTM 1.29b / Total Stockholder Equity 4.41b)
RoCE = 37.42% (EBIT 1.67b / Capital Employed (Equity 4.41b + L.T.Debt 40.4m))
RoIC = 28.98% (NOPAT 1.28b / Invested Capital 4.41b)
WACC = 7.67% (E(20.16b)/V(20.23b) * Re(7.69%) + D(69.4m)/V(20.23b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -4.84%
[DCF] Terminal Value 73.48% ; FCFF base≈906.8m ; Y1≈644.6m ; Y5≈344.8m
[DCF] Fair Price = 50.40 (EV 7.00b - Net Debt -3.03b = Equity 10.03b / Shares 199.0m; r=7.67% [WACC]; 5y FCF grow -33.99% → 2.90% )
EPS Correlation: 28.31 | EPS CAGR: 37.19% | SUE: -0.45 | # QB: 0
Revenue Correlation: 90.88 | Revenue CAGR: 21.18% | SUE: 3.48 | # QB: 6
EPS next Quarter (2026-03-31): EPS=1.41 | Chg7d=+0.017 | Chg30d=-0.243 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=7.42 | Chg7d=-0.006 | Chg30d=-0.533 | Revisions Net=-6 | Growth EPS=+9.1% | Growth Revenue=+8.9%
EPS next Year (2027-12-31): EPS=8.69 | Chg7d=+0.038 | Chg30d=-0.253 | Revisions Net=-2 | Growth EPS=+17.2% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: -0.75 (1 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.3%)
[Growth] Growth Spread = +17.3% (Analyst 19.0% - Implied 1.6%)
P/E Forward = 12.5
P/S = 3.922
P/B = 3.9021
P/EG = 0.1286
Revenue TTM = 5.14b USD
EBIT TTM = 1.67b USD
EBITDA TTM = 1.76b USD
Long Term Debt = 40.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 69.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.03b USD (from netDebt column, last quarter)
Enterprise Value = 16.65b USD (20.16b + Debt 69.4m - CCE 3.58b)
Interest Coverage Ratio = 686.5 (Ebit TTM 1.67b / Interest Expense TTM 2.43m)
EV/FCF = 12.29x (Enterprise Value 16.65b / FCF TTM 1.35b)
FCF Yield = 8.13% (FCF TTM 1.35b / Enterprise Value 16.65b)
FCF Margin = 26.35% (FCF TTM 1.35b / Revenue TTM 5.14b)
Net Margin = 25.03% (Net Income TTM 1.29b / Revenue TTM 5.14b)
Gross Margin = 91.80% ((Revenue TTM 5.14b - Cost of Revenue TTM 421.6m) / Revenue TTM)
Gross Margin QoQ = 90.88% (prev 92.75%)
Tobins Q-Ratio = 2.39 (Enterprise Value 16.65b / Total Assets 6.96b)
Interest Expense / Debt = 0.84% (Interest Expense 582.0k / Debt 69.4m)
Taxrate = 23.25% (90.7m / 389.9m)
NOPAT = 1.28b (EBIT 1.67b * (1 - 23.25%))
Current Ratio = 3.32 (Total Current Assets 5.02b / Total Current Liabilities 1.52b)
Debt / Equity = 0.01 (Debt 69.4m / totalStockholderEquity, last quarter 5.17b)
Debt / EBITDA = -1.72 (Net Debt -3.03b / EBITDA 1.76b)
Debt / FCF = -2.24 (Net Debt -3.03b / FCF TTM 1.35b)
Total Stockholder Equity = 4.41b (last 4 quarters mean from totalStockholderEquity)
RoA = 20.75% (Net Income 1.29b / Total Assets 6.96b)
RoE = 29.15% (Net Income TTM 1.29b / Total Stockholder Equity 4.41b)
RoCE = 37.42% (EBIT 1.67b / Capital Employed (Equity 4.41b + L.T.Debt 40.4m))
RoIC = 28.98% (NOPAT 1.28b / Invested Capital 4.41b)
WACC = 7.67% (E(20.16b)/V(20.23b) * Re(7.69%) + D(69.4m)/V(20.23b) * Rd(0.84%) * (1-Tc(0.23)))
Discount Rate = 7.69% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -33.33 | Cagr: -4.84%
[DCF] Terminal Value 73.48% ; FCFF base≈906.8m ; Y1≈644.6m ; Y5≈344.8m
[DCF] Fair Price = 50.40 (EV 7.00b - Net Debt -3.03b = Equity 10.03b / Shares 199.0m; r=7.67% [WACC]; 5y FCF grow -33.99% → 2.90% )
EPS Correlation: 28.31 | EPS CAGR: 37.19% | SUE: -0.45 | # QB: 0
Revenue Correlation: 90.88 | Revenue CAGR: 21.18% | SUE: 3.48 | # QB: 6
EPS next Quarter (2026-03-31): EPS=1.41 | Chg7d=+0.017 | Chg30d=-0.243 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=7.42 | Chg7d=-0.006 | Chg30d=-0.533 | Revisions Net=-6 | Growth EPS=+9.1% | Growth Revenue=+8.9%
EPS next Year (2027-12-31): EPS=8.69 | Chg7d=+0.038 | Chg30d=-0.253 | Revisions Net=-2 | Growth EPS=+17.2% | Growth Revenue=+10.3%
[Analyst] Revisions Ratio: -0.75 (1 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 1.6% (Discount Rate 7.9% - Earnings Yield 6.3%)
[Growth] Growth Spread = +17.3% (Analyst 19.0% - Implied 1.6%)